Journal: | Annals of hepatology |
Database: | PERIÓDICA |
System number: | 000417072 |
ISSN: | 1665-2681 |
Authors: | Flores Calderón, Judith1 Morán Villota, Segundo1 Ramón García, Guillermo1 González Romano, Berenice1 Bojórquez Ramos, María del Carmen2 Cerdán Silva, Laura3 Hernández Frías, Pablo3 |
Institutions: | 1Instituto Mexicano del Seguro Social, Centro Médico Nacional Siglo XXI, México, Distrito Federal. México 2Instituto Mexicano del Seguro Social, Centro Médico Nacional de Occidente, Guadalajara, Jalisco. México 3Instituto Mexicano del Seguro Social, Centro Médico Nacional La Raza, México, Distrito Federal. México |
Year: | 2012 |
Season: | May-Jun |
Volumen: | 11 |
Number: | 3 |
Pages: | 364-368 |
Country: | México |
Language: | Inglés |
Document type: | Artículo |
Approach: | Analítico, descriptivo |
English abstract | Identifying liver fibrosis is important to evaluate the severity of liver damage and to establish a prognosis. Utility of non-invasive markers of liver fibrosis has been proved in adults but there are few reports in children. The aim of this study was to evaluate Fibrotest® score and APRI suitability to identify children with liver fibrosis. Material and methods. 68 children with chronic liver disease requiring liver biopsy were prospectively included from three 3rd-level pediatric hospitals. The same pathologist evaluated all liver biopsies; fibrosis degree was determined by METAVIR score. Serum samples were obtained to determine Fibrotest® and APRI. AUROC were used to determine cut-off and differentiate between advanced fibrosis (METAVIR F3, F4) and no fibrosis (F0). Results. 68 biopsies were evaluated; METAVIR > F3 was identified in 26 (38%). Non invasive liver fibrosis markers to differentiate between advanced and no fibrosis were: Fibrotest® AUROC = 0.90 (95% CI 0.77-1.00) (cut-off value 0.35) sensitivity 88.00% (95% CI 68-96) and specificity 80% (95% CI 29-98); and for APRI AUROC = 0.97 (95% CI 0.92-1.00) (cut-off value 0.82), sensitivity 88% (95% CI 68-96) and specificity = 100% (95% CI 46-100). Conclusion. These results suggest the utility of Fibrotest® and APRI to identify advanced fibrosis; they can be recommended to select patients for liver biopsy and during patient follow-up |
Disciplines: | Medicina |
Keyword: | Gastroenterología, Diagnóstico, Pediatría, Enfermedad hepática crónica, Fibrosis hepática, Marcadores diagnósticos |
Keyword: | Gastroenterology, Diagnosis, Pediatrics, Chronic liver disease, Liver fibrosis, Diagnostic markers |
Full text: | Texto completo (Ver PDF) |